RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.
about
Glioblastoma research: US and international networking achievements.RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases.Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis.Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy.
P2860
RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@en
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@nl
type
label
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@en
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@nl
prefLabel
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@en
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@nl
P2093
P2860
P356
P1433
P1476
RSK2 activity mediates gliobla ...... l target for new therapeutics.
@en
P2093
Amanda M Prechtl
Dirk Geerts
Florian J Sulzmaier
Michelle L Matter
Pengfei Jiang
Santosh Kesari
Shirley Young-Robbins
P2860
P304
79869-79884
P356
10.18632/ONCOTARGET.13084
P407
P50
P577
2016-11-04T00:00:00Z